Paraquat Lawsuit Update October 2026: MDL 3004 Status, Settlement Talks & Who Can Still File
As of October 2026, the paraquat products liability litigation is in settlement administration: more than 6,600 actions remain pending in MDL No. 3004 before Judge Nancy J. Rosenstengel in the Southern District of Illinois, following a confidential Master Settlement Agreement executed on September 3, 2025. Bellwether trials are on hold while claims are processed.
Key Facts
- 6,602 actions were pending in MDL No. 3004 as of October 1, 2026, with 8,495 filed historically.
- A confidential Master Settlement Agreement was executed on September 3, 2025; many plaintiffs declined their offers.
- The first federal bellwether cases were dismissed in April 2024 after the court excluded the plaintiffs’ general causation expert under Daubert.
- The U.S. Supreme Court declined review of Syngenta Crop Protection, LLC v. Nemeth on October 6, 2025.
- Syngenta will end global paraquat production by June 2026; roughly 32 countries have already banned the herbicide.
What the Litigation Is About
Paraquat is a fast-acting herbicide sold in the United States for decades, most recognizably as Gramoxone. For years, farmworkers and licensed applicators mixed, sprayed, and handled it — often, they allege, with little appreciation of the danger.
The core allegation: exposure to paraquat causes Parkinson’s disease, and the companies that made and sold it knew the risk yet failed to warn users. Named defendants include Syngenta Crop Protection LLC, Syngenta AG, and Chevron U.S.A. Inc., the companies tied to the herbicide’s manufacture and distribution.
The science behind the claim rests largely on a 2011 study by Tanner and colleagues, published in Environmental Health Perspectives, which found roughly 2.5 times the odds of Parkinson’s disease among people who had used paraquat. The U.S. Environmental Protection Agency has said it has not found a clear link between paraquat and Parkinson’s from labeled uses — a disagreement that has defined the litigation from the start. Readers new to the case may find our earlier guide to MDL 3004 and who qualifies useful background.
Where MDL 3004 Stands in October 2026
An MDL — multidistrict litigation — is a federal procedure that consolidates similar lawsuits from across the country before a single judge for pretrial proceedings. The paraquat MDL, formally In re Paraquat Products Liability Litigation, MDL No. 3004, No. 3:21-md-3004-NJR, has sat before Judge Nancy J. Rosenstengel in the U.S. District Court for the Southern District of Illinois since its consolidation in June 2021.
Per the Judicial Panel on Multidistrict Litigation’s docket report, 6,602 actions were pending as of October 1, 2026, out of 8,495 filed historically. Non-settling plaintiffs have been ordered to meet with a special master, and the court entered a Lone Pine order — a case-management tool requiring plaintiffs to produce early evidence supporting their claims before full discovery proceeds.
A parallel state-court track is also moving: more than 1,100 paraquat cases are proceeding in the Philadelphia Court of Common Pleas, with some reports placing the number near 2,080.
The Master Settlement Agreement of September 2025
The defining development of the past year was the execution of a Master Settlement Agreement on September 3, 2025. Its terms are confidential, and, critically, many plaintiffs declined the offers extended to them.
Federal bellwether trials are on hold while settlement administration proceeds and the court works through the non-settling claims. That pause is procedural, not an ending: thousands of cases remain live in the docket, and the court continues active management through its special master. Settlement dynamics of this kind — confidential master agreements, substantial decliner cohorts, parallel case management — have shaped other chemical-exposure MDLs as well; our October 2026 update on the Zantac litigation traces a parallel story.
The Bellwether Setback of 2024
A bellwether trial is a test case selected from among the many consolidated claims so that both sides can gauge how juries respond to the evidence. In the paraquat MDL, the first federal bellwethers never reached a jury. In April 2024, the court dismissed them after excluding the plaintiffs’ general causation expert under the Daubert standard, the federal rule governing whether expert testimony is reliable enough for a jury to hear.
This needs saying plainly: the dismissals were not a finding that paraquat is safe. They were a ruling about the admissibility of one body of expert evidence at that stage of the litigation. Plaintiffs’ counsel has continued building its evidentiary record, while the Philadelphia state-court track moves under its own evidentiary rules. For context on how expert gatekeeping has reshaped other mass torts, see our October 2026 update on the AFFF firefighting foam litigation.
Who Can Still File — and What Comes Next
New claims are still being evaluated. The people at the center of this litigation are those with documented paraquat exposure — farmworkers and applicators who mixed or sprayed the herbicide — who were later diagnosed with Parkinson’s disease. But filing deadlines vary by state and can quietly expire, so anyone who believes they were exposed should consult a licensed attorney promptly rather than assuming the settlement window will wait for them.
Lawyers handling these cases work on contingency: there is no upfront fee, and the firm is paid only if it recovers compensation. That arrangement exists because the claimants here are ordinary working people, not corporations with litigation budgets.
The road ahead is administrative: settlement processing, special-master review of non-settling claims, and continued state-court movement in Philadelphia. Meanwhile, the product itself is leaving the market — Syngenta has announced it will end global paraquat production by June 2026, Vermont has banned it, California is phasing it out, and roughly 32 countries have already prohibited it.
Our video team explains major litigation developments on the Problem Solved YouTube channel.
This article is general information, not legal advice. Mass-tort litigation turns on facts, deadlines, and the law of your state — consult a licensed attorney before making any decision about a potential claim.
Who Benefits From This — and Who Does Not
As of October 2026, the paraquat litigation is in settlement administration: more than 6,600 actions remain pending in MDL No. 3004, following a confidential Master Settlement Agreement executed on September 3, 2025, with many plaintiffs having declined their individual offers. This guide helps some readers act — and warns others off false expectations.
Who benefits:
- Farmworkers and licensed applicators with documented paraquat exposure and a Parkinson's diagnosis. The core allegation is that exposure to paraquat, sold most recognizably as Gramoxone, causes Parkinson's disease and that the companies failed to warn users — so documented exposure followed by diagnosis is at the heart of a claim.
- People who mixed, sprayed, or handled the herbicide over time. New claims are still being evaluated by plaintiffs' firms, so anyone who believes they were exposed should speak with a licensed attorney promptly rather than waiting, since filing deadlines vary by state and can expire.
- Plaintiffs who declined their offers and are following the current process. Those who declined are proceeding through a special-master process under a Lone Pine order while settlement administration continues.
Who does not benefit:
- People without documented exposure or a Parkinson's diagnosis. Exposure followed by diagnosis is what this litigation turns on.
- Anyone expecting a guaranteed or finalized payout. The September 2025 agreement's terms are confidential, many plaintiffs declined their offers, and no reliable public per-case figures exist because most settlements are confidential — the litigation is not over.
- Anyone reading the 2024 bellwether dismissals as a finding that paraquat is safe. The first federal bellwether cases were dismissed in April 2024 after the court excluded the plaintiffs' general causation expert under Daubert — a ruling on evidence admissibility, not a safety finding — and the science debate continues.
Related reading: AFFF Firefighting Foam Lawsuit October 2026 Update.
Frequently Asked Questions
Is the paraquat settlement finalized?
A Master Settlement Agreement was executed on September 3, 2025, but its terms are confidential and many plaintiffs declined their individual offers. Those who declined are proceeding through a special-master process under a Lone Pine order, and settlement administration continues — so the litigation is not over.
Can I still file a paraquat lawsuit in 2026?
New claims are still being evaluated by plaintiffs’ firms, but filing deadlines (statutes of limitation) vary by state and can expire, so anyone who believes they were exposed should speak with a licensed attorney promptly rather than waiting.
How much compensation can I receive from the paraquat lawsuit?
Compensation varies widely by case; no reliable public per-case figures exist because most settlements are confidential. Any firm quoting you a guaranteed amount before reviewing your records is not someone you should trust.
Did the court’s 2024 rulings mean paraquat is safe?
No. The April 2024 dismissals followed the exclusion of the plaintiffs’ general causation expert under the Daubert standard — a ruling about the admissibility of evidence, not a finding that paraquat is safe. The underlying scientific debate continues.
Who benefits most from this paraquat guide — and who does it not help?
It helps farmworkers and licensed applicators with documented paraquat exposure and a Parkinson's diagnosis, including people who mixed, sprayed, or handled Gramoxone over time, and plaintiffs who declined their offers and are following the special-master process under a Lone Pine order. It does not help people without documented exposure or a diagnosis, anyone expecting a guaranteed or finalized payout — the September 2025 agreement's terms are confidential and many plaintiffs declined — or anyone reading the 2024 dismissals as a safety finding, since those followed the exclusion of the general causation expert under Daubert.
How do I start a paraquat claim?
Do not wait for the settlement window: new claims are still being evaluated, but filing deadlines vary by state and can expire, so speak promptly with a licensed attorney rather than waiting. Settlement administration continues and the litigation is not over, so the first step is a prompt, confidential conversation about your exposure and diagnosis — not an assumption about any amount, since no reliable public per-case figures exist.